Hearing Loss in Cisplatin Treated Patients

David Freyer, DO

David Freyer, DO, of the Children's Hospital of Los Angeles and professor of pediatrics at Keck School of Medicine, University of Southern California, explains the mechanisms by which hearing loss can occur in children (and adults) treated with cisplatin, a chemotherapy agent commonly used in oncology. 
As Dr Freyer explains in this video taken during the ASPHO's 30th Annual Meeting in Montreal, Canada, the ototoxicity can be particular harmful to the survivors of pediatric cancer.
Sodium thiosulfate (STS) is a water-soluble thiol compound and acts as a chemical reducing agent. Administration of STS may protect against platinum-induced ototoxicity, as it has been shown in animal models and in patients.
Printer Printing...